HCPCS code J9277: Pembrolizumab injection, with hyaluronidase, per 1 mg2026 Medicare rate & RVUs

Medicare allowed amount for participating (non-QP) physicians, before deductible, coinsurance and claim adjustments. Not a patient’s bill or a hospital charge.

What J9277 covers

This code identifies a subcutaneous cancer immunotherapy product combining pembrolizumab, an immune checkpoint inhibitor, with berahyaluronidase alfa-pmph. It is used in treatment regimens for cancers for which pembrolizumab is selected. Oncology practices and infusion centers typically report the drug for an administered dose; it is not the code for the injection-administration service itself.

CMS assigns this HCPCS Level II code physician fee schedule status E, meaning it is excluded from the physician fee schedule. When Medicare covers the drug, payment is under another method: CMS classifies it as a Part B drug generally paid using the quarterly Average Sales Price drug pricing files. Coverage is left to the Medicare contractor's judgment. Each billing unit represents 1 mg of pembrolizumab; report units based on the pembrolizumab amount administered.

This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.

Where J9277 pays more and less

The same RVUs, adjusted for each area’s costs. Open a locality for its calculation, history and nearby areas.

109 of 109 payment localities

J9277 rates by state

Office rate range in each state. Select a state to see its payment localities.

How the J9277 rate is calculated

Each of J9277’s three RVUs is multiplied by a geographic index (GPCI) for the payment locality, added up, and multiplied by the conversion factor. Drag the indexes or enter a ZIP to see what moves the rate.

Payment rules and modifiers for J9277

J9277 has no global surgery period, no multiple-procedure, bilateral or assistant-at-surgery adjustment, and no professional/technical split. What changes the payment is where the service happens: the place of service on the claim decides whether Medicare pays the office or the facility rate.

J9277 compared with similar codes

How to choose

J9271PembrolizumabPer 1 mg

Both codes involve pembrolizumab, but J9277 identifies the combination with berahyaluronidase alfa-pmph for subcutaneous injection; J9271 identifies pembrolizumab for intravenous administration.

J9289Nivolumab-hyaluronidasePer 2 mg

J9289 identifies nivolumab with hyaluronidase, not pembrolizumab. The drugs have distinct treatment indications and are not interchangeable solely because both are subcutaneous formulations.

J9272Dostarlimab injectionPer 10 mg

J9272 is dostarlimab, a different immunotherapy drug. Select the code for the drug actually administered, not by therapeutic class alone.

Codes related to J9277

Related codes aren’t interchangeable: bill the code that matches the service performed.

Where these rates come from

FeeBase calculates base physician payments from CMS work, practice-expense and malpractice RVUs, adjusted by each locality’s geographic indexes and the conversion factor. Services without a published rate are labeled, never given a made-up amount. Amounts are Medicare allowed amounts before claim adjustments: not a patient’s bill or a commercial rate.

CMS RVU26D · effective Oct 1, 2026 through the day before Jan 1, 2027

Open CMS sourceHow we calculate rates